Table 2.
Anti-SARS-CoV-2 spike protein receptor binding domain (S-RBD) IgG levels at different time points in SAID patients and HC.
| T3 | T6 | T9 | ||
|---|---|---|---|---|
| HC | S-RBD IgG, kBAU/L (IQR) | 2719 (724–4154) * | 275 (149–443) | 1077 (529–3409) * |
| female | 2934 (1690–4796) * | 345 (137–514) | 1150 (529–3755) ° | |
| male | 1878 (413–3334) # | 197 (147–296) | 828 (497–2943) # | |
| SAID, patients | S-RBD IgG, kBAU/L (IQR) | 1400 (637–3206) * | 86 (45–198) | 2316 (1155–6681) * |
| female | 1600 (852–3079) # | 74 (43–378) | 2316 (1155–6938) ° | |
| male | 1261 (595–3548) # | 87 (42–152) | 1969 (594–5005) # |
S-RBD IgG levels in COVID− SAID patients and COVID− HC were measured at T3, T6, and T9 using CLIA Maglumi 2000 plus as described in Materials and Methods. Data are reported as median and IQR. p was calculated according to the Kruskal-Wallis test. Dunn post hoc test, * p < 0.0001, ° p < 0.001, # p < 0.01 vs. T6. HC, healthy controls; SAID, Systemic autoinflammatory diseases; IQR, interquartile range.